Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic ...

Astellas has turned to AviadoBio to further boost its gene therapy pipeline, paying the British biotech $50 million in equity ...

The Japanese big pharma adds the new gene therapy candidate to its pipeline in a US$50 million deal in equity and upfront ...

The agreement leverages King's College London spin-out company's expertise in developing targeted gene therapy for ...

UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license ...

Astellas Pharma is spreading its bets in neurodegenerative disorders, committing $50 million to AviadoBio for the opportunity to license its lead program, an experimental gene therapy for a type ...

Aviadobio Ltd. has entered a potential $2.18 billion license and commercialization agreement for its frontotemporal dementia gene therapy, AVB-101, with Astellas Pharma Inc. Astellas is making a $20 ...

Large pharmaceutical companies were out in force at this week’s 2024 Cell & Gene Meeting on the Mesa, as they look to expand ...

AviadoBio is a central nervous system (CNS) gene-therapy company pioneering novel applications to slow and potentially arrest neurodegenerative diseases. The company has developed novel gene ...

3. Astellas pays $50M for option on AviadoBio's dementia gene therapy Continuing its investments in cell and gene therapy, ...

AviadoBio and Astellas Pharma announced an exclusive option and license agreement for AVB-101, an investigational, AAV-based gene ...